Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by Laterline Therapy

Research Leaders

5 sponsors active, led by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 2 (2)

Trial Status

Active Not Recruiting1
Completed1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT04736485Phase 2Completed

Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)

NCT04554771Phase 2Active Not Recruiting

Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy

NCT05802407Not ApplicableRecruiting

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer

Showing all 3 trials

Research Network

Common Treatments

  • Laterline Therapy1
  • External Beam Radiotherapy1
  • Paclitaxel1
  • Tocilizumab1
  • Perioperative Treatment1

Active Sponsors

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1
  • National Cancer Institute, France1
  • Noordwest Ziekenhuisgroep1
  • Centre Francois Baclesse1
  • Peking Union Medical College Hospital1

Top Investigators

Related Conditions

  • Gastric Cancer By Ajcc V8 Stage1
  • Oesophageal Adenocarcinoma1
  • Esophageal Adenocarcinoma1
  • Pancreatic Cancer1

Activity Timeline